Navigation Links
Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds

Introduced at Informex 2008

REDWOOD CITY, Calif., Jan. 29 /PRNewswire/ -- Codexis(R), Inc., a private biotechnology company and leading developer of clean manufacturing processes, today introduced the Codex(TM) MicroCyp Plate, a research productivity tool which can be used by pharmaceutical companies to more rapidly identify and synthesize drug metabolites and novel drug lead candidates.

The Codex(TM) MicroCyp Plate is being introduced this week at Informex 2008 ( in New Orleans. It is based on a platform technology for preparing and identifying drug metabolites (substances produced during drug metabolism). These metabolites are generated by bacterial cytochrome P450 enzymes licensed by Codexis from the California Institute of Technology (see Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology from California Institute of Technology, August 29, 2007).

The research tool introduced today is based on a specific cytochrome (cyp) enzyme, 102A1, which metabolizes fatty acids in the microbe. Today's launch expands the Codexis research product family, adding metabolite screening and synthesis as well as lead diversification to a full suite of tools for improving pharmaceutical process development efficiency.

"This platform can be used by pharmaceutical companies to more efficiently identify and produce safer, more efficacious drugs earlier in the drug development process," said Peter Seufer-Wasserthal, Ph.D., Vice President and General Manager, Codexis Pharma Services. "Conventional methods for metabolite identification and production and lead diversification are difficult and time-consuming. Our customers now have an efficient way to make multiple compounds for testing at a reduced cost. They can also identify toxic metabolites before time and money are spent on problematic drug candidates."

Drug metabolites are produced by the body during the break-down (metabolism) of drugs. Primary metabolites are largely formed in the liver by human P450 enzymes to aid in elimination of a drug from the body. In some cases, metabolites can be toxic, while for other drugs, "active" metabolites have shown improved efficacy and lower toxicity than the administered drug substance. The US Food and Drug Administration now recommends metabolic characterization for all new investigational human therapeutics.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit

Contact. Justin Jackson,, Burns McClellan, 212-213-0006, or Lyn Christenson,, 650-421-8144.

SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Appoints Singapore Laboratories Managing Director
2. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
3. Bruce Pasternack Elected to Codexis Board
4. Codexis Opens Singapore Laboratory
5. Rothwell, Wolf Elected to Codexis Board
6. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
7. Novozymes Launches Enzyme to Reduce Acrylamide in Food
8. Enova Medical Launches Exos Corporation
9. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
10. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
11. ThirdBiotech Networking Group Launches
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):